CytomX Therapeutics, Inc. (CTMX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.
CytomX Therapeutics, Inc. (NASDAQ:CTMX)‘s stock had its “hold” rating restated by equities researchers at Oppenheimer Holdings, Inc. in a research note issued on Wednesday.
Several other research analysts also recently commented on the stock. Bank of America Corporation lifted their target price on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday. Nomura lifted their price target on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $37.00 price target (up previously from $26.00) on shares of CytomX Therapeutics in a report on Wednesday. ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, Jefferies Group LLC set a $25.00 price target on shares of CytomX Therapeutics and gave the company a “buy” rating in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $32.67.
Shares of CytomX Therapeutics (CTMX) traded up 21.53% on Wednesday, reaching $23.09. 3,353,455 shares of the company traded hands. CytomX Therapeutics has a one year low of $9.85 and a one year high of $24.67. The stock’s market capitalization is $851.26 million. The stock’s 50 day moving average price is $16.92 and its 200-day moving average price is $15.62.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The firm had revenue of $8.75 million during the quarter, compared to analysts’ expectations of $4.95 million. Equities analysts forecast that CytomX Therapeutics will post ($1.49) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “CytomX Therapeutics, Inc. (CTMX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/04/cytomx-therapeutics-inc-ctmx-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.
In related news, CFO Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total value of $37,500.00. Following the sale, the chief financial officer now owns 19,626 shares in the company, valued at $294,390. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sean A. Mccarthy sold 4,781 shares of CytomX Therapeutics stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total transaction of $71,715.00. Following the completion of the sale, the insider now owns 9,026 shares in the company, valued at approximately $135,390. The disclosure for this sale can be found here. In the last quarter, insiders sold 100,306 shares of company stock worth $1,924,746. 8.00% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its holdings in CytomX Therapeutics by 28.6% in the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 1,434 shares in the last quarter. First Quadrant L P CA bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at $160,000. Goldman Sachs Group Inc. bought a new stake in shares of CytomX Therapeutics during the 1st quarter valued at $190,000. Cubist Systematic Strategies LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at $174,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of CytomX Therapeutics during the 1st quarter valued at $206,000. Institutional investors and hedge funds own 59.97% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.